{"id":"W4403665847","doi":"10.1200/jco.24.00529","title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Medac","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Internal medicine; Trastuzumab emtansine; Oncology; Hazard ratio; Breast cancer; Clinical endpoint; Pertuzumab; Lapatinib; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01107528,0.0004206729,0.005584887,0.0005599049,0.0001024045,0.0001101193,0.0007197357,0.000450456,0.004814645],"category_scores_gemma":[0.007234652,0.000265539,0.0005187726,0.0008339033,0.000733742,0.0008153813,0.0001790796,0.003120462,0.00003407447],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00147727,"about_ca_system_score_gemma":0.009231953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005870114,"about_ca_topic_score_gemma":0.0005547061,"domain_scores_codex":[0.9870741,0.004898979,0.005636747,0.0006828966,0.0009821609,0.0007251158],"domain_scores_gemma":[0.9869318,0.00912204,0.001509676,0.0003297075,0.0009687425,0.001138043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7477456,0.008920825,0.0001464834,0.0001430596,0.001497594,0.004217531,0.0004115533,0.000005123169,0.001644658,0.00008396988,0.00312562,0.2320579],"study_design_scores_gemma":[0.9210438,0.06854355,0.0009264947,0.001004869,0.001107175,0.000968468,0.000187565,0.0008712982,0.0004559974,0.0002070753,0.004407804,0.0002759445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742411,0.001671907,0.000195107,0.01458317,0.003387424,0.004470543,0.0002649804,0.00004833257,0.001137459],"genre_scores_gemma":[0.9882396,0.003881803,0.002585806,0.001219269,0.002820431,0.0002896034,0.00004578965,0.0001002529,0.0008173858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.231782,"threshold_uncertainty_score":0.9999797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2651344660519626,"score_gpt":0.5945402876781979,"score_spread":0.3294058216262353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}